Differences between cemiplimab and cemiplimab

Cemiplimab（Cemiplimab) is actually the Chinese translation of Cemiplimab. The two are essentially the same drug and there is no difference in pharmacological mechanism. Cemiplimab is a fully humanized IgG4 monoclonal antibody jointly developed by Regeneron Pharmaceuticals and Sanofi, with the trade name Libtayo. It is mainly used to treat cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma, non-small cell lung cancer (NSCLC) and certain advanced or recurrent tumors. This drug is a PD-1 (programmed death protein-1) inhibitor that blocks the binding of PD-1 to its ligand PD-L1, thereby activating the immune response of T cells against tumor cells to achieve anti-tumor purposes.

The name Cemiplimab is actually the transliteration ofCemiplimab. Different countries and regions often use different translation standards when introducing drugs, and may also use slightly different names, but the ingredients and usage of drugs remain the same. In mainland China, cimepilimab has not yet been commercially sold on a large scale, but its clinical research and import registration are in progress, and it is expected that it will gradually become popular in the domestic market in the next few years.

Cemiplimab has shown strong anti-tumor activity in international clinical trials, especially in advanced cutaneous squamous cell carcinoma for which no treatment options have been previously available. Its objective response rate (ORR) can reach more than 40%, and its side effects are relatively controllable. As a member of the PD-1 inhibitor family, it has a similar mechanism to drugs such as Nivolumab and Pembrolizumab, but has differences in indications, applicable populations, and safety performance. For example, Cemiplimab is currently approved by the FDA mainly for specific types of skin cancer and non-small cell lung cancer, while other PD-1 inhibitors are more widely used in melanoma, liver cancer, or Hodgkin lymphoma.

Reference materials:https://www.libtayohcp.com/